Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

March 2, 2018: By Jon Swedien

Aerie Pharmaceuticals anticipates it will launch Rhopressa in the middle of Q2-2018, the company announced Feb. 28.

Aerie forecasts the open-angle glaucoma and ocular hypertension treatment will net between $20 million and $30 million in 2018, the company said. Rhopressa gained US FDA approval in December 2017.

The company said it expects to gain preferred formulary coverage for the majority of commercial payers for Rhopressa by late 2018, with most of the Medicare Part D coverage expected to start in 2019.

Aerie said it has commercial product and sample inventory currently on hand to cover more than a full year of expected demand. The company also plans to have its sales force of 100 territory managers in place and fully trained in time for the launch, said Vicente Anido Jr., PhD, Aerie’s chairman and CEO.

Aerie forecasts its cash burn for 2018 will range between $200 million to $210 million. That includes adjusted total operating expenses in the range of $155 million to $160 million, and capital and inventory build expenditures in the range of $45 million to $50 million, the company said.

Aerie had approximately $250 million in cash, cash equivalents, and investments as of Dec. 31, 2017, the company said.

In January, Aerie raised approximately $136 million in equity offering net proceeds from the issuance of 2.3 million shares, the company reported.

Rhopressa (netarsudil ophthalmic solution) 0.02% is a rho-associated protein kinase (rho kinase, or ROCK) inhibitor, a new class of medications proposed to lower intraocular pressure (IOP) by directly increasing trabecular outflow. The eye drop is administered once a day.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023